Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.

Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy - 1 Nov 1996

Gabrilovich D I, Cunningham H T, Carbone D P

Abstract excerpt

Mice bearing palpable tumors expressing a mutant p53 gene were treated with intravenous injection of mutant p53-specific peptide-pulsed dendritic cells (DCs). Control groups were treated with control peptide-pulsed DCs. All mice received three injections of 10(5) DCs on days 0, 5, and 10 after the start of the therapy. Half of the animals in each group were also treated with intraperitoneal injections of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptides
Share to Amino Acid Sequence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred BALB C

Share to Molecular Sequence Data

Share to Mutation

Share to Neoplasms, Experimental

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 9041460
DOI: 10.1097/00002371-199611000-00005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer.PMID 9041460Read ↗

Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.Semantic proximity Read ↗

DNA vaccination with a mutated p53 allele induces specific cytolytic T cells and protects against tumor cell growth and the formation of metastasis.Semantic proximity Read ↗

Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response.Semantic proximity Read ↗

Gene Therapy of Cancer Based on Interleukin 12Semantic proximity Read ↗

Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.Semantic proximity Read ↗

Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers.Semantic proximity Read ↗

Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.Semantic proximity Read ↗

Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.Semantic proximity Read ↗

CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice.Semantic proximity Read ↗

Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.Semantic proximity Read ↗

Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade Neuroblastoma.Semantic proximity Read ↗

Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.